A Proof of Concept (POC) Study, Phase II, Open Label, Randomized, Standard Care - Controlled, Single Center Study Evaluating the Safety and Efficacy of Human, Alpha-1 Antitrypsin (AAT) [GLASSIA®] Treatment in First Lung Transplantation

Trial Profile

A Proof of Concept (POC) Study, Phase II, Open Label, Randomized, Standard Care - Controlled, Single Center Study Evaluating the Safety and Efficacy of Human, Alpha-1 Antitrypsin (AAT) [GLASSIA®] Treatment in First Lung Transplantation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Lung transplant rejection
  • Focus Adverse reactions; Proof of concept
  • Sponsors Kamada
  • Most Recent Events

    • 08 Jan 2018 According to a Kamada media release, next interim results following one-year of treatment for all patients, expected in the second half of 2018, as well as top-line results from the Phase 2, anticipated in the second half of 2019.
    • 08 Jan 2018 Interim results from the first six months of treatment of the initial 16 patients presented in a Kamada Media Release.
    • 13 Nov 2017 According to a Kamada media release, the company expected to have an interim analysis from this study before end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top